(Q39515384)

12 September 2017

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways (English)

1 reference

12 September 2017

chronic myeloid leukemia

0 references

1 reference

Deborah L White

7

0 references

author name string

Carine Tang

1

1 reference

12 September 2017

Lisa Schafranek

2

1 reference

12 September 2017

Dale B Watkins

3

1 reference

12 September 2017

Wendy T Parker

4

1 reference

12 September 2017

Sarah Moore

5

1 reference

12 September 2017

Jodi A Prime

6

1 reference

12 September 2017

Timothy P Hughes

8

1 reference

12 September 2017

30 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

52

1 reference

12 September 2017

11

1 reference

12 September 2017

2139-2147

1 reference

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

12 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Interaction of imatinib mesilate with human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Molecular biology of double-minute chromosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Double Minute Chromosomes and the Homogeneously Staining Regions in Chromosomes of a Human Neuroblastoma Cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Oncogene amplification in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Fusion tyrosine kinases: a result and cause of genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.591013

10.3109/10428194.2011.591013

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference